HLA-B ∗15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: A pooled-data analysis and meta-analysis

Epilepsia

Volumn 55, Issue 11, 2014, Pages e120-e124

  Khor, Amy Hui Ping ^a,b   Lim, Kheng Seang ^a   Tan, Chong Tin ^a   Wong, Su Ming ^a   Ng, Ching Ching ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Carbamazepine; HLA B 15:02; Indian; Malaysia; Steven Johnson syndrome

Indexed keywords

CARBAMAZEPINE; HLA B 15 02; HLA B ANTIGEN; UNCLASSIFIED DRUG; HLA B15 ANTIGEN;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HLA TYPING; HUMAN; INDIA; INDIAN; MALAYSIA; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; EPIDERMIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; META ANALYSIS; MIDDLE AGED; NECROSIS; PATHOLOGY; RISK FACTOR; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; EPIDERMIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-B15 ANTIGEN; HUMANS; INDIA; MALE; MIDDLE AGED; NECROSIS; RISK FACTORS; STEVENS-JOHNSON SYNDROME; YOUNG ADULT;

EID: 84922337354     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12802     Document Type: Article

References (17)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
2. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012;78:734-739.
3. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-278.
4. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428:486.
5. Wang Q, Zhou J, Zhou L, et al. Association between HLA-B∗1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 2011;20:446-448.
6. Cheung YK, Cheng SH, Chan EJM, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 2013;54:1307-1314.
7. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B∗1502 allele in Thai population. Epilepsia 2008;49:2087-2091.
8. Chang CC, Too CL, Murad S, et al. Association of HLA-B∗ 1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011;50:221-224.
9. Then SM, Rani ZZM, Raymond AA, et al. Frequency of the HLA-B∗ 1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pac J Allergy Immunol 2011;29:290-293.
10. Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39:D913-D919.
11. Reich D, Thangaraj K, Patterson N, et al. Reconstructing Indian population history. Nature 2009;461:489-494.
12. Basu A, Mukherjee N, Roy S, et al. Ethnic India: a genomic view, with special reference to peopling and structure. Genome Res 2003;13:2277-2290.
13. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B∗1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-582.
14. Venkatesan SA, Rajappa SM. HLA-B∗1502 genotyping in carbamazepine induced Stevens Johnson's syndrome and toxic epidermal necrolysis. Vienna, Austria. J Neurol Sci 2013;333:e62.
15. Amstutz U, Ross CJD, Castro-Pastrana LI, et al. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther 2013;94:142-149.
16. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;94:324-328.
17. Kaniwa N, Saito Y, Aihara M, et al. HLA-B∗1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients: marker for CBZ-induced SJS/TEN in Japanese. Epilepsia 2010;51:2461-2465.